TrialStudy of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
Trial details
- Registry ID
- NCT04387461
- Phase
- Phase 2
CGON
CG Oncology, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
4Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinNCT04387461 | CGON | Phase 2 | Completed | 2023-03-07Actual |
| Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinNCT04452591 | CGON | Phase 3 | Active not recruiting | 2030-06-16Estimated |
| A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTNCT06111235 | CGON | Phase 3 | Active not recruiting | 2026-11Estimated |
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCNCT06567743 | CGON | Phase 2 | Recruiting | 2027-03-31Estimated |
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Trial details
- Registry ID
- NCT04452591
- Phase
- Phase 3
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Trial details
- Registry ID
- NCT06111235
- Phase
- Phase 3
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Trial details
- Registry ID
- NCT06567743
- Phase
- Phase 2
Latest recorded trial changes
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235 · CG Oncology, Inc.
Primary completion date changed
− Before
Jun 2026
+ After
Nov 2026
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT04452591 · CG Oncology, Inc.
Primary completion date changed
− Before
24 Dec 2027
+ After
16 Jun 2030
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235 · CG Oncology, Inc.
Primary completion date changed
− Before
Jan 2028
+ After
Jun 2026